Fig. 5: The CRISPR-engineered CAR-T therapy.
From: Gene editing in cancer therapy: overcoming drug resistance and enhancing precision medicine
A CRISPR-based strategies to prevent GvHD include suppressing TCR and MHC-I expression to eliminate the alloreactive potential of donor T-cells. B CRISPR-mediated silencing of CD52 and TCR in CAR-T cells confers resistance to HvGR and prevents GvHD, respectively.
